Items tagged with Vaccines
New tuberculosis vaccine candidate found (post)
Hyderabad, March 9, 2016: A group of scientists has found a new candidate for tuberculosis (TB) vaccine, which could be more effective than the existing BCG vaccine, the first and only vaccine for the fatal disease.
Interrupted BCG vaccination is a major threat to global child health (post)
At a meeting of the WHO Child TB Subgroup in Cape Town, South Africa, in December, 2015, critical BCG vaccine shortages were reported in many countries. These shortages started in 2013 and continued into 2015. The United Nations Children's Fund (UNICEF) is the main supplier of BCG vaccine to tuberculosis-endemic countries. During this period, two of its four suppliers, the Statens Serum Institute (SSI) in Denmark and the Serum Institute of India experienced technical difficulties that resulted in reduced production capacity. UNICEF reported shortages of 8 million doses in 2013, 23 million doses in 2014, and 17 million doses in 2015.1 Delegates from many countries reported interruption of BCG vaccination programmes due to local stock-outs resulting from unreliable supply.
Optimization of a human Bacille Calmette-Guérin challenge model: a tool to evaluate antimycobacterial immunity (post)
Abstract
Biomarker discovery offers hope for new TB vaccine (post)
A team of scientists led by Oxford University have made a discovery that could improve our chances of developing an effective vaccine against Tuberculosis.
The researchers have identified new biomarkers for Tuberculosis (TB) which have shown for the first time why immunity from the widely used Bacillus Calmette-Guérin (BCG) vaccine is so variable. The biomarkers will also provide valuable clues to assess whether potential new vaccines could be effective.
Aeras provides update on Phase 2 trial (C-040-404/TUB09) of H4:IC31 (post)
The Sanofi Pasteur-Aeras Joint Steering Committee for the Phase 2 trial (C-040-404/TUB09) convened on 14 June 2016 to review and discuss the recommendations of the study’s independent Data Monitoring Committee (DMC).
Vacancy: Scientific communications officer at TBVI (post)
TuBerculosis Vaccine Initiative (TBVI) is recruiting an early to mid-career dynamic person for the position of Scientific communications officer.
Vaccinations against smallpox and tuberculosis are associated with better long-term survival: a Danish case-cohort study 1971–2010 (post)
Abstract
TB vaccine development in the 21st century takes new approaches (post)
DURBAN, South Africa – “Can we control tuberculosis without a vaccine?” asked Willem Hanekom, of the Bill & Melinda Gates Foundation, Saturday, and answered his own question: “No.”
Toward an effective TB vaccine: Analysis of the immune response to a promising candidate (post)
BCG, the only currently approved TB vaccine, has been around for almost a century and is only partially effective. When given to children, BCG is estimated to prevent 20% of infections and to protect half of the infected individuals from developing active TB, and protection fades over time. Given the complicated TB treatment, the rise of adult TB cases in conjunction with the HIV epidemic, and increasing multidrug resistant TB strains, a new and better vaccine is a global health priority. A study published on July 28th in PLOS Pathogens dissects the immune response in mice to an experimental vaccine and shows why it is highly effective.
Page 6 of 32 · Total posts: 0
←First 5 6 7 Last→